Haryana, India

Sachin Musmade

This inventor holds 1 USPTO granted patent. Top assignee: Fresenius Kabi Oncology Limited. Active years: 2022.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sachin Musmade: Innovator in Cancer Treatment

Introduction

Sachin Musmade is a notable inventor based in Haryana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. His innovative work has led to the creation of a patented process that enhances the preparation of a vital cancer medication.

Latest Patents

Sachin Musmade holds a patent for the "Process for the preparation of ribociclib and its salts." This invention relates to a method for producing ribociclib, a compound used in cancer therapy. The patent also introduces novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. Furthermore, it encompasses pharmaceutical compositions that include these crystalline forms along with acceptable carriers, aimed at improving cancer treatment outcomes.

Career Highlights

Sachin is currently employed at Fresenius Kabi Oncology Limited, where he continues to work on innovative solutions in oncology. His role at the company allows him to collaborate with other experts in the field, contributing to advancements in cancer therapies.

Collaborations

Some of Sachin's coworkers include Sarbjot Singh Sokhi and Govind Singh. Their collective expertise fosters a collaborative environment that enhances the development of effective cancer treatments.

Conclusion

Sachin Musmade's contributions to the pharmaceutical industry, particularly in cancer treatment, highlight his role as an innovative inventor. His patented processes and ongoing work at Fresenius Kabi Oncology Limited demonstrate his commitment to improving patient outcomes through scientific advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…